Wolverine Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Wolverine Asset Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,494	Closed	-$156K	–	1729
2018 Q3	$156K	Buy	+21,494	New	+$108K	﹤0.01%	1225
2017 Q2	–	Sell	-10,494	Closed	-$98.5K	–	1416
2017 Q1	$142K	Buy	+10,494	New	+$94.4K	﹤0.01%	897

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Wolverine Asset Management's PLX Position: Q4 2018 in Review

Wolverine Asset Management sold out of Protalix BioTherapeutics (PLX) in Q4 2018, closing a stake of 21,494 shares — an estimated $156K sold.

Wolverine Asset Management first reported a position in PLX in Q1 2017 and held it in 2 quarters. The position peaked at $156K in Q3 2018. 36 funds tracked by Wall St. Rank hold PLX as of Q4 2018.

Wolverine Asset Management reported no remaining Protalix BioTherapeutics position as of Q4 2018 after selling out during the quarter.
Wolverine Asset Management sold 21,494 Protalix BioTherapeutics shares in Q4 2018, an estimated $156K.
Wolverine Asset Management first reported a position in Protalix BioTherapeutics in Q1 2017 and held it in 2 quarters.
Wolverine Asset Management's Protalix BioTherapeutics position peaked at $156K in Q3 2018.
36 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2018.

Based on Wolverine Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.